

EATRIS-Plus Summer School

in Personalised Medicine

17-20 April 2023



Our flagship project **eatris** aims to build further capabilities and deliver innovative scientific tools to support the long-term sustainability strategy of EATRIS as one of Europe's key European Research Infrastructures for Personalised Medicine.

Organised by:










European infrastructure for translational medicine






Programme 17 April Day 1

Registration & gathering	09.00-09.30
Opening remarks & welcome	09.30-10.45
Retrospective from EATRIS-Plus Summer School Round of Introductions I (participants)	10.00-10:45
Multi-modal biomarkers - Session I	10.45-13.15
State-of-the-Art & Introduction	10.45-11.15
Impact on diagnostics & disease monitoring	11.15-11.45
Coffee break	11.45-12.15
Multi-modal biomarkers - Session I	12.15-13.15
Clinical implementation	12.15-12.45
Ethics, legal and regulatory aspects	12.45-13.15
Lunch	13.15-14.30
Workshop: EATRIS-Plus & the multi-omics toolbox	14.30-16:30
Welcome drink	16:30-18:00



Programme 18 April Day 2

Digital Health & Emerging Technologies - Session II	09.25-13.00
State-of-the-Art & Introduction	09.30-10.00
Good practices on health data and integration - Personalised medicine in Estonia – moving from research to practice	10.00-10.30
Coffee break	10.30-11.00
Digital Health & Emerging Technologies - Session II	11.00-13.00
Interoperability & harmonisation of electronic health data - a successful	11.00-11.30
example Digital health/Wearable innovation	11.30-12.00
Practical case discussion (health data protection)	12.00-13.00
Lunch	13.00-14.00
Lunch	13.00 14.00
Introdcutions II	14.00-14.45
Workshop: e-Health & wearable devices	14.15-16:15
workshop. e-nearth & wearable devices	14.15-10.15
A discussion with clinicians, patients associations & a company Diabetes in a 360° view	



Programme 19 April Day 3

In silico tools in research & Personalised Medicine - Session III	09.30-12.30
Computational models in pharmaceutical development In silico medicine in disease management	09.30-10.00 10.00-10.30
Coffee break	10.30-11.00
In silico tools in research & Personalised Medicine - Session III	11.00-12.30
Showcase of a successful product In silico tools for regenerative medicine	11.00-11.30 11.30-12.00
In silico tools for medical device development	12.00-12.30
Lunch	12.30-14.00
Workshop: Opportunities/challenges/solutions solving with in silico tools	14.00-16.00
Dinner	17.30



Programme 20 April Day 4

Keynote Lecture: Multimodel biomarkers in medicine - What's next?	09.30-10.30
Coffee break	10.30-10.45
Interactive Sessions: Lessons learned on Multimodel biomarkers and Diagnostics	10.45-11.45
Closing remarks & feedback	11.45-12.15
Lunch box	12.15



17-20 April 2023 - Lisbon

Speakers



Rui S. Ivo

President of INFARMED, I.P., National Authority of Medicines and Healthcare Products Governor EATRIS PT

Rui Santos Ivo is the President of INFARMED since June 2019 and a member of the Management Board of the EMA and the Executive Board of EUnetHTA. He is the Vicechair of the Valletta Permanent Technical Committee/Valletta Declaration. He is also an Invited Assistant Professor of Medicines Regulation, at the Faculty of Pharmacy of the University of Lisbon. He is an external elected member of the General Council of the University of Coimbra. Previously he was President (2014/2016) and Vice-President (2011/2014) of the Central Administration of the Health System (ACSS,IP) at the Ministry of Health, in Portugal. He was Coordinator of the Hospital Reform Project Team (2012/2015) and chaired the Governance College for the Public Health Subsystems (2015/2016). R. S. Ivo started his professional career as a hospital pharmacist at Hospital de Egas Moniz, in Lisbon. In 1993 he joined INFARMED, where he held various responsibilities, like Vice-president (1994-2000; 2016-2019) and President (2002-2005). In 2000/2002 he worked as Administrator at the Directorate of the European Medicines Agency and in 2006/2008 he worked for the European Commission as Administrator at the Pharmaceuticals Unit, Directorate General for Enterprise and Industry. He was the first Chairman of the European Union Heads of Medicines Agencies Management Group (2004-2005). His awards include: Imofariz Prize, Personality of the Year in the Pharmaceutical Sector (2004), European Correspondent Member, Académie Nationale de Pharmacie, France (2014) and Medal (gold) for distinguished Services, Ministry of Health (2015).



17-20 April 2023 - Lisbon



Claudia Faria

Claudia Faria received her medical degree from the University of Coimbra (Portugal) in 2001. She did her training in the Department of Neurosurgery at Hospital de Santa Maria – Centro Hospitalar Universitário Lisboa Norte (CHULN, Lisbon, Portugal), and became board certified Neurosurgeon in 2010. Due to her interest in the genetics of brain tumours, particularly in the pediatric population, she did her PhD at the Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children (Toronto, Canada) with Professor James T. Rutka. Using the genetic signatures of medulloblastoma (a malignant pediatric brain tumour) she studied the mechanisms of tumour recurrence and dissemination and identified novel small molecule inhibitors that were successfully tested in preclinical models of the disease.

Upon returning to Lisbon in 2014, Claudia Faria became a clinician-scientist working as a Consultant Neurosurgeon at CHULN, as a researcher at Instituto de Medicina Molecular João Lobo Antunes (iMM) and as an Invited Assistant Professor of Neurosurgery and Neurology at Faculdade de Medicina da Universidade de Lisboa. She founded the Brain Tumor Bank at Biobanco-iMM in 2012 and became Co-Director of Biobanco-iMM in 2018, is responsible to supervise and coordinate the activities of scientific and technical committees, fostering the collaboration between medical doctors and researchers and promoting dissemination and fundraising actions for scientific research.

In 2016 Claudia Faria was appointed President of the Portuguese Neuro-Oncology Association (APNO) and Chair of the Young Investigators and Innovators Group of the European Society for Pediatric Oncology - Brain Tumor Group (SIOPE BTG).

Since 2018 she is the Portuguese representative on the Board of National Directors of the European translational network EATRIS-ERIC and in November 2020 she was elected Chair of the Board of National Directors of EATRIS.



17-20 April 2023 - Lisbon



Irena Mlinarič-Raščan Prof. Ph.D. MPharm.

Prof. dr. Irena Mlinarič-Raščan, MPharm, is dean of the Faculty of Pharmacy, University Ljubljana, Slovenia, and National Director of EATRIS.SI and President of the UNESCO National Committee. She is a full professor in pharmacogenomics, immunology and cell biology. Irena completed two postdoctoral fellowships at the Mount Sinai Hospital Toronto and at the Tokyo University and was a guest professor at the Universities of Bern and Vienna. Her research work involves pharmacogenomics approaches in the individualisation of leukaemia and lymphoma therapies, focusing on thiopurine personalised therapy, identification of novel target molecules including prostaglandin receptor 4, proteasome and immunoproteasome, which further serve for lead design and optimisation.



Emanuela Oldoni

Emanuela is an enthusiastic scientist with a passion for new challenges. She is mainly interested in translational medicine because it permits a continuous exchange between the clinic and laboratory aspects. She got her PhD in molecular and translational medicine in 2018, at the University of Milan, leading a project about biomarkers in neurodegenerative diseases where she applied different methodologies and multi-omics approaches. After, she obtained a prestigious post-doc research fellowship, funded by ECTRIMS, about biomarkers and genetics in multiple sclerosis providing a rationale for personalised medicine. After 5 productive years as a researcher at academic laboratories, between Italy and Belgium, since Jan 2020 she has been working as Scientific Programme Manager at EATRIS. At EATRIS she combines her strong scientific background and her soft skills to facilitate industry-academic collaborations pursuing a common aim: innovation and improvement of human life.



17-20 April 2023 - Lisbon



André Albergaria

André Albergaria is a researcher specialising in Oncology. His scientific expertise is focused on epigenetic regulatory mechanisms in breast cancer, cancer therapy resistance, and biomarker discovery and validation. André holds a PhD from the Institute of Health and Life Sciences from the University of Minho and was a PhD resident at the Imperial College School of Medicine of London, UK, between 2006 and 2008. André has a Post-Graduation in BioBusiness, from AMC Graduate School and Amsterdam BioMed Cluster, Netherlands and worked as an Investment Consultant in the LifeSciences & MedTech Team of the company Portugal Ventures.

During the last 20 years of his scientific career, André has published more than 33 papers in peer-reviewed international journals. Actually, André is a Professor at the Faculty of Medicine of the University of Porto and is the coordinator of the i3S Translational Research and Industry Partnerships Office (Research and Innovation Unit), a group that works on the interface between the health care/pharma industry, clinicians and academic research teams. André is a member of the Portuguese Coordination of the Research & Innovation Agenda on Health and Clinical and Translational Research. He is a project evaluator for several public and private entities, including pharma companies, and is an expert member of the H2020 SC1 Programme Committee, a health expert at Perin – Portugal in Europe Research and Innovation Network and developed and contributed as a scientific expert to several European organisations/Consortium such as ICPerMed.



17-20 April 2023 - Lisbon



Alain van Gool

Alain van Gool is professor Personalized Healthcare and heads the Translational Metabolic Laboratory at the Radboud university medical center, with a strong passion in the application of biomarkers in translational medicine and personalised healthcare. After his study (biochemistry, 1991) and PhD (molecular biology, 1996) Alain worked at a mix of academia, pharmaceutical industries, applied research institutes, university medical centers in Europe, Asia and USA. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development and applications in translational scientific research.

Alain is a strong believer of open innovation networks and thrives to work with specialists to translate basic research to applied science. With that background, he currently also acts as Strategic Advisor to the Executive Board of Radboudumc, cocoordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences), is Chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine), is co-initiator of Health-RI (the Netherlands Health Research Infrastructure for Personalised Medicine and Health), and Project leader and PI of the Netherlands X-omics Initiative, thus contributing to the organisation and coordination of local, national and European technology infrastructures. Complementing his daily work, he enjoys contributing to scientific advisory boards of start-up enterpreneurs, multinational companies, translational organisations, funding agencies and conference organisers.



17-20 April 2023 - Lisbon



Laura García-Bermejo

M. Laura García Bermejo, PhD in Cellular Biology and Genetics (1997, Alcala University and CSIC) and Master in Senior Management of Scientific Institutions (IESE 2019) is Head of the group Biomarkers and Therapeutic Targets at Ramon y Cajal Health Research Institute since 2006. Her multidisciplinary group includes basic and clinical researchers and is focused on translational research providing tools for implementation in clinical practice. She has launched 2014 a Core Facility for biomarkers, included in the IRYCIS Services Portfolio. In addition, Dr García Bermejo is co-chair of the Biomarkers Platform of EATRIS since 2016. From 2009 to 2012, Dr García Bermejo was appointed as Assistant Professor of Physiology at the School of Medicine in Alcala University and she is currently a professor in several university Master's Degrees (UAH, UAM, San Pablo CEU). Since December 2019, she is the Scientific Director of IRYCIS, leading more than 1,400 researchers.



17-20 April 2023 - Lisbon



Alfonso Valencia

Prof. Alfonso Valencia is ICREA research Professor, Director of the Life Sciences Department of the Barcelona Supercomputing Center, and Director of the Spanish National Bioinformatics Institute INB-ELIXIR-ES. His research interest is the development of Computational Biology methods and their application to biomedical problems. Some of the computational methods he developed are considered pioneering work in areas such as biological text mining, protein coevolution and more recently epigenetic and disease networks. He participates in some of the key cancer related international consortia. In terms of community services, he is one of the initial promoters of what is now the ELIXIR infrastructure, founder of the Spanish Bioinformatics network and founder member and former president of ISCB the professional association of Bioinformaticians and the Executive Editor of the main journal in the field - Bioinformatics OUP.



17-20 April 2023 - Lisbon



José C. Machado

José C. Machado (JCM) is Associate Professor in the Faculty of Medicine of Porto, vicepresident of the Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), and Coordinator of the Cancer Program at i3S. He studied Biology at the University of Porto and developed his PhD in the Universities of Tubingen, Germany and Porto, Portugal. The scientific question that drives JCM's research group is how genetically encoded information in cancer cells is shared among the diverse cellular constituents of a tumour, and how that affects the heterogeneity and plasticity of cancer cells. JCM has been awarded research projects by the Portuguese Foundation for Science and Technology (FCT), by the Portuguese Agency for Innovation (ADI), by the Portuguese Ministry of Health, by Worldwide Cancer Research and by the European Union. JCM is also the head of R&D at the molecular genetics laboratory of the IPATIMUP Diagnostics Unit. This is one of the reference laboratories in Portugal for the detection of cancer biomarkers, genetic diagnosis of hereditary cancer syndromes and pathology. As of April 2021, JCM (Scopus Author ID 7102792651) co-authors 166 publications in indexed journals with IF, with 11530 total citations, and with an h-index of 44.



17-20 April 2023 - Lisbon



Sulev Reisberg

Sulev Reisberg, Ph.D., is an accomplished expert in health informatics and personalised medicine with a strong background in software development. Dr. Reisberg has dedicated his career to developing and implementing systems that enable machines to work with health and genomics data. He has leveraged his extensive experience to build information systems for health registries in Estonia and analyse electronic health records and genomic data from central health databases and the Estonian Biobank. He is an active member of the OHDSI/OMOP common data model community and is currently leading the development of national personalised medicine infrastructure in Estonia. Dr. Reisberg's current research investigates disease progression patterns and has also worked on polygenic risk scores and pharmacogenetics. His notable contributions to the field of personalised medicine include winning the ICPerMed "Best Practice in Personalised Medicine" Recognition in 2019 for his paper "Translating genotype data into clinical pharmacogenetic recommendations: challenges and solutions." Dr. Reisberg's expertise and dedication continue to drive progress in the field of health informatics and personalised medicine in Estonia and beyond.



17-20 April 2023 - Lisbon



Tero Aittokallio

Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape.

In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Biostatistics at University of Oslo in 2019. He is also a group leader at Institute for Cancer Research, Oslo University Hospital, where his group develops computational-experimental approaches for personalised medicine.

Tero is leading one of the demonstrator projects for REMEDi4ALL, the European project on Drug Repurposing. He will also present his work in the project to the summer school participants.



17-20 April 2023 - Lisbon



Pablo Serrano

Pablo Serrano is the Director of Quality and Planning of the Hospital Universitario 12 de Octubre of the Health System of the Community of Madrid. He has held management positions in hospitals and does research on electronic health records and interoperability. He has participated in national and European projects on the representation of health information and its use in care and research. His group is currently working on the use of health data for multiple purposes.

Find out more here and here.



17-20 April 2023 - Lisbon



Julio Acero Prof Ph.D MD DMD

Julio Acero is the Head of the Department of Oral and Maxillofacial Surgery of the Ramon y Cajal and the Puerta de Hierro University Hospitals in Madrid, Spain, Full Professor of Surgery at the Alcala University of Madrid and Member of the Research Group on Tissue Engineering and Regenerative Medicine of The Ramon y Cajal Research Institute IRYCIS. He studied Medicine and Dentistry and obtained his PhD at the university in Madrid being distinguished as Doctor Honoris Causa by the University of Iasi, Romania and by the National University of Athens, Greece. Fellow Ad eundem of the Royal College of Surgeons of England as well as Fellow and Examiner of the International Board for the Certification of Specialists in Oral and Maxillofacial Surgery (IBCSOMS). Prof Acero is a Member of the Spanish National Academy of Dental Sciences and foreign Member of the National Academy of Dentistry of Argentina. His special fields of interest are oncologic and reconstructive surgery of the head and neck including the skull base as well as bone regeneration. He has lectured and published widely in these fields and has been appointed as invited Professor in different universities around the world including the official appointments of External Full Professor of the National University of Athens (Greece), Honorary Professor at the University of Ferrara (Italy), the University of Belgrade (Serbia), the University of Bucharest (Romania) and the National University of Nordeste (Corrientes, Argentina). Visiting Professor at the University of Beijing (China), Messina (Italy), Malaya University at Kuala Lumpur (Malaysia), University of Florida in Jacksonville and the Vanderbilt University (USA). Distinguished Fellow Award of the IAOMS, Honorary Member of the Latin-American Association of Oral and Maxillofacial Surgery (ALACIBU), Honorary Fellow of the American Association of Oral and Maxillofacial Surgeons (AAOMS) and of the Australian and New Zealand Association of Oral and Maxillofacial Surgeons (ANZAOMS), Distinguished Fellow of the Association of Oral and Maxillofacial Surgeons of India, Honorary Member of the National OMFS Societies of Argentina, Bulgaria, Croatia, Greece, Italy, Turkey and the North Macedonian Association of Maxillofacial Surgeons. IAOMS Outstanding Committee Member Award presented in the ICOMS, Shanghai 2009, Humanitarian Award of the American College of Oral and Maxillofacial Surgeons, presented in Puerto Rico 2016.



17-20 April 2023 - Lisbon



Alberto Lima Alves

Professional Activity

1995-degree in medicine at the Faculty of Medicine of the University of Porto.

1996-1997 – General residence at Hospital São João (HSJ), Porto.

1998-2004-Infectious diseases specialization in the Infectious Disease department HSJ. (Compulsory military duty from April to October 1998)

2004-2005-Working as specialist in the Infectious Diseases department of Joaquim Urbano Hospital, Porto.

2005-2015 – Hospital specialist in the Infectious Disease department HSJ, Porto, working in the areas of general ward, internal consulting, outpatient and intensive care unit. Coordinator of the Postgraduate Training of the department from 2006 to 2015. 2009-2010-Intensive care training program HSJ. Specialty of intensive care medicine after national examination in November 2010.

2013 – Responsible for the design and creation of the Unit of Prevention and Control of Infection and Antimicrobial Resistance (UPCIRA) HSJ (first antibiotic stewardship unit in Portugal). Implementation of an antimicrobial stewardship program in the hospital. 2014-2022 Coordinator of UPCIRA HSJ.

2014- Member of the Pharmacy and Therapeutic Commission of HSJ.

2015- Degree of Consultant in Infectious Diseases after national examination.

2016-2019- Assistant Clinical Director HSJ and chairman of the Pharmacy and Therapeutic Committee of HSJ.

2016-2022-Member of the National Pharmacy and Therapeutic Commission.

2016-2022- Chairman of the Portuguese National Pharmacy and Therapeutic Commission.

2017-2022- Member of the Portuguese Health Technologies Assessment Commission

2020-2022- Member of the Portuguese Medicines Evaluation Commission

2018-2022 - Member of the Quality and Safety Committee HSJ

2022- ...- Vice-President Executive Board, INFARMED – National Authority of Medicines and Health Products, I.P.



17-20 April 2023 - Lisbon



Toni Andreu

Toni is specialised in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research. After working in Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d'Hebron Research Institute where he became Director of the Neurosciences Research Program.

He has also been extremely active in the field of policy-making and held positions as the Director of the Spanish National Institute of Health Carlos III, creating the national program for personalised medicine. He has also been the CEO of the Bellvitge Hospital, one of the most important University hospitals in Spain, as well as the Director General for Research and Innovation at the Catalan Ministry of Health.

Toni is now in this second term as the Scientific Director at EATRIS, the European Advanced Infrastructure for Translational Research.



17-20 April 2023 - Lisbon



Heitor Manuel Ribeiro Costa

In the area of medicines and health products, he worked at INFARMED, successively, assuming technical functions at the National Center for Pharmacovigilance, Executive Secretary of the Medicines Evaluation Commission, Coordinator of the Health Products Surveillance Unit, Director of Health Products Evaluation, President of the Evaluation Commission for in vitro Diagnostic Medical Devices and Director of Medicines and Health Products, with coordination of the departments of Community Affairs, Medicines for Human Use, Veterinary Medicines and Medical Devices.

He has been a member of several committees and working groups of the Commission and the Council of the European Union, as well as the European Medicines Agency (EMA), on human and veterinary medicines, medical devices, cosmetics and homeopathic products. He was President of the Medical Devices Market Surveillance Coordination Group of the Competent Authorities for Medical Devices (European Commission) and Coordinator of the Working Group on Breast Implants (INFARMED / Directorate-General for Health / Consumer Institute / Portuguese Medical Association).

In 2004/2005, he was Advisor to the Secretary of State for Health, having, among others, duties to monitor the medicine policy and the activity of INFARMED and coordinate the Working Group to regulate the dispensing by the ambulatory pharmacies of some medicines dispensed exclusively in the hospital pharmacy. Between June 2005-July 2009 was Medical Director of the Medinfar Group. In August 2009, he joined sanofi-aventis as Director of Institutional Relations, Communication & Market Access.

Between November 2011-November 2021 he was Executive Director of APIFARMA.

Between June 2012 and June 2013, he was a member of the Economic and Social Policy Committee of EFPIA, between June 2013 and June 2015 of the Executive Committee of EFPIA and between June 2015 and November 2021 of the European Markets Committee of EFPIA.



17-20 April 2023 - Lisbon



Tiia Tallinen

Tiia Tallinen, M.Sc.(Eng), Group Leader and Quality manager, entered her role at the Tampere University Regea Tissue Center in 2003. She holds a degree in Industrial engineering and management. In addition, she has educated herself in the University of Granada, Spain (Master programme in Manufacturing of Advanced Therapy Medicinal Products, Specialization of Quality Control Manager, 2012). She is currently the group leader of the GMP-unit as well as a deputy responsible person for the clinical tissue bank. She has worked as a project manager for various types of projects ranging from the set-up of a GMP quality management system to cleanroom construction and regulatory process management. She has carried the main responsibility for the process and correspondence of several regulatory filings for cell and tissue-based products with both Fimea and EMA. She has also held administrative responsibility for a university institute, gained experience from the commercialisation aspects of cell-based therapies as well as participated in the establishment of a spin-off company.

17-20 April 2023 - Lisbon



Helena BaiaoNational Coordinator of EATRIS Portugal

eatrisportugal@infarmed.pt



Eliis Keidong
EU Project Manager at
EATRIS C&S
eliiskeidong@eatris.eu

